Medacta Group SA · SIX:MOVE

Medacta Group SA — FY2020 Earnings Presentation

23 slides from Medacta Group SA's earnings presentation, Mar 31, 2021

  1. Slide 1: FY 2020 Financial Results

    FY 2020 Financial Results 31 March 2021

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the presentation does not purport to be comprehensive. Please refer to the Medacta 2020 Annual Report available on our website at

  3. Slide 3: Francesco Siccardi, Chief Executive Officer

    FRANCESCO SICCARDI Chief Executive Officer FY 2020 Financial Results

  4. Slide 4: 2020 Highlights

    2020 Highlights* * Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency", "EBITDA", "Adjusted EBITDA" or “CORE EBITDA”, "Free Cash Flow", “Adjusted Free Cash Flow”, “Net

  5. Slide 5: FY 2020 Medacta's Achievements

    FY 2020 Medacta’s Achievements  Revenues equal to Euro 302.5 million, down only 2.1% on constant currency basis, significantly above market decline1, after growth of 7.6% on a constant currency basis in 2H driven by both pent-up demand and new customers acquired  Adjusted EBITDA of Euro 88.1 milli

  6. Slide 6: Redesigned Marketing and Education Offering

    Redesigned Marketing and Education Offering Thanks to new marketing initiatives and digital education programs we were able to keep existing surgeons fully involved and engage new customers, leveraging national experts 2’900+ surgeons attended our online and digital education programs with significa

  7. Slide 7: Strong R&D focus with 30+ new Products cleared

    Strong R&D focus with 30+ new Products cleared #30+ new Products were cleared (CE or FDA) in 2020, including:  In the Hip product line  Completion of the renewal of primary implant offering and expansion of revision product range  Launch of new solutions for 3D pre-operative planning and intra-op

  8. Slide 8: NextAR Surgical Platform

    NextAR™ Surgical Platform  First surgeries were successfully performed in Australia and in the US, and the number of reference centers supporting future worldwide expansion is increasing  The platform technology perfectly fits with sustainability of healthcare systems and particularly with US ambu

  9. Slide 9: Corrado Farsetta, Chief Financial Officer

    CORRADO FARSETTA Chief Financial Officer FY 2020 Financial Results

  10. Slide 10: FY Revenue Bridge by Product Line

    FY Revenue Bridge by Product Line1 (€m) -6.1% -4.1% 46.6% 14.6% (€m) 14.3; 28.9; 5% 9% 153.1; 106.2; 51% 35% 2 Hip Knee Extremities Spine  Core business (Hip and Knee) was affected by postponement of elective procedures in 1H, partially compensated by an effective backlog recovery  The Extremities

  11. Slide 11: FY Revenue Bridge by Geographic Area

    FY Revenue Bridge by Geographic Area1 (€m) -6.0% -1.0% 9.2% -29.2% (€m) 8.5; 3% 72.0; 24% 129.3; 43% 92.7; 30% Europe NA APAC ROW  In Europe the most affected markets were France, Italy and Belgium; the “DACH” area recorded the smallest impact with Germany growing over the prior year  In NA our in

  12. Slide 12: FY 2020 P&L: Remarkable Profitability

    FY 2020 P&L: Remarkable Profitability1 PROFIT & LOSS STATEMENT (€m) FY 2019 A FY 2020 A Revenues 310.6 302.5 Cost of Sales (86.9) (88.2) GROSS PROFIT 223.7 214.3 GROSS PROFIT MARGIN 72.0% 70.8% Research and Development expenses (7.6) (6.8) Sales and Marketing expenses (127.1) (110.1) General and Adm

  13. Slide 13: FY 2020 Investments for Future Growth

    FY 2020 Investments for Future Growth FY 2020 Investments €34.2m % of Revenues 11.3% (€m) Other  Investments in instruments and in the Intangibles;3 development of new implants and 2.0; 6% surgical instruments to feed new R&D customers started in 2020 and sustain the Investments; 8.1; 24% growth 

  14. Slide 14: FY 2020 Positive Free Cash Flow Generation after Investments

    FY 2020 Positive Free Cash Flow1 Generation after Investments for Future Growth ADJUSTED FREE CASH FLOW (€m) FY 2019 A FY 2020 A PROFIT FOR THE YEAR 11.9 37.1 P&L Adjustments: Income tax expenses 1.8 2.8 Depreciation and amortisation 33.7 37.0 Other P&L non-cash transactions 17.0 9.6 Movements in wo

  15. Slide 15: Net Financial Debt: Low Leverage to Face New Investments

    Net Financial Debt: Low Leverage1,2 to Face New Investments to Grow Leverage 1.15x 0.95x (€M) 105.6 83.3 Net Debt at 31 December 2019 Net Debt at 31 December 2020 Notes: 1. For a reconciliation of Alternative Performance Measures please refer to section headed “Alternative Performance Measures” of t

  16. Slide 16: Francesco Siccardi, Chief Executive Officer

    FRANCESCO SICCARDI Chief Executive Officer FY 2020 Financial Results

  17. Slide 17: 2021 Outlook

    2021 Outlook  We will continue to monitor the evolution of the Covid-19 pandemic and impact on our reference market, while remaining committed to our future growth  Despite uncertainty remaining in some geographies, we believe Medacta is well positioned to deliver growth as a result of our global

  18. Slide 18: Q&A

    Q&A FY 2020 Financial Results

  19. Slide 19: Adedacta

    Adedacta Adedacta International

  20. Slide 20: Appendix

    APPENDIX FY 2020 Financial Results

  21. Slide 21: Consolidated Statement of Profit or Loss

    Consolidated Statement of Profit or Loss 21

  22. Slide 22: Consolidated Statement of Comprehensive Income

    Consolidated Statement of Comprehensive Income 22

  23. Slide 23: Consolidated Statement of Cash Flows

    Consolidated Statement of Cash Flows 23

Medacta Group — FY2020 Earnings Presentation on 6ix